Meeting
2013 ASCO Annual Meeting
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
Authors
Ian Flinn
Sarah Cannon Research Institute, Nashville, TN
Ian Flinn , Eva Kimby , Finbarr E. Cotter , Francis J. Giles , Ann Janssens , Elisa Jacobsen Pulczynski , Loic Ysebeart , Andrzej Pluta , Jose Antonio Garcia Marco , Kerry Taylor , Carolyn Owen , David Michael Johnson , Maria Aiello , Roger D. Dansey , Ronald L. Dubowy , Jeffrey Alan Jones
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01659021
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS7131)
DOI
10.1200/jco.2013.31.15_suppl.tps7131
Abstract #
TPS7131
Poster Bd #
46C
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Jeffrey Alan Jones
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
First Author: Gilles A. Salles